Committed to Safeguarding Vision and Enhancing Lives

Ocular Therapeutix is a biopharmaceutical company developing transformational treatments that enhance people’s vision and quality of life through consistent and sustainable drug delivery.
Our Technology Press Releases
Dextenza White Logo
Retinal Diseases
inner eye

THERAPEUTIC AREAS

Retinal Diseases

Researching preservative-free, sustained-release implants to replace the need for repeated injections

Glaucoma
Doctor Checking Patient's Eyes

THERAPEUTIC AREAS

Glaucoma

Researching biodegradable hydrogel alternative to the lifelong burden of daily eye drops

Ocular Surface Diseases
lab staff

THERAPEUTIC AREAS

Ocular Surface Diseases

Researching sustained-release inserts to provide lasting treatment without preservatives for dry eye disease

Ophthalmic Surgery
Ophthalmic Surgery

THERAPEUTIC AREAS

Ophthalmic Surgery

Ongoing investigation of innovative ELUTYXTM technology to transform treatments in postoperative care

Hyrdro

ELUTYX™ Technology

Our Elutyx technology is a versatile platform employed to create sustained-release therapies that may expand treatment options across multiple ocular conditions.

Our Technology
Our Pipeline

Helpful Resources

Events & Presentations
Learn more about Ocular Therapeutix at upcoming events and corporate presentations
Scientific & Medical Presentations
Read the latest scientific and medical presentations on Ocular Therapeutix emerging therapies
Investor FAQ
Find answers to commonly asked questions about Ocular Therapeutix
blue eye fibers

Ocular Therapeutix is growing quickly. We offer exciting career opportunities and comprehensive benefits for talented candidates.

See All Open Positions
Careers at Ocular
Press Releases
01 | 00
November 8, 2023
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
November 7, 2023
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
November 1, 2023
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
October 24, 2023
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
October 3, 2023
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
September 6, 2023
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
August 9, 2023
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 7, 2023
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
July 24, 2023
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results